Waxman, a tough critic of industry, is retiring

Share this article:
Henry Waxman
Henry Waxman

California Democrat Henry Waxman, one of the strongest FDA overseers and drug industry critics on Capitol Hill, will step down when the House of Representatives, where he's spent 20 terms, adjourns for the mid-term elections.

“I first ran for office because I believe government can be a force for good in people's lives,” Waxman said in a statement. “And I will leave the House of Representatives with my conviction intact.”

Recently, Waxman helped advance legislation (Drug Quality and Security Act) to strengthen FDA's authority to stop dangerous drug compounding and to track pharmaceuticals through the supply chain.

In reviewing his accomplishments, Waxman said: “I took on the pharmaceutical companies that did not want competition and joined with Senator Orrin Hatch (R-UT) to write the law that created the generic drug industry. My orphan drug legislation led to treatments for hundreds of rare diseases… and in 2010, when I was chair of the Committee on Energy and Commerce, one of my lifelong dreams was finally achieved: Congress passed the Affordable Care Act.”

Waxman said there are elements today in Congress that he dislikes. “I am embarrassed that the greatest legislative body in the world too often operates in a partisan intellectual vacuum,” he said. “But I am not leaving out of frustration with Congress. Even in today's environment, there are opportunities to make real progress.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.